Several of the S&P 500's stocks fit both bills at this time, with a bunch of them boasting the makings of a true "forever" ...

Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...

On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

'R2 is looking straight at Discovery's starboard side...' ...

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

At an investor summit in New York on Tuesday, activist investor Starboard called out Pfizer's PFE board of directors to take ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...